Product
EDG-5506
Aliases
EDG-5506 10 mg, EDG-5506 12.5 mg, EDG-5506 5 mg, EDG-5506 Dose 1 (4 other aliases)
6 clinical trials
12 indications
Indication
Becker Muscular DystrophyIndication
Duchenne muscular dystrophyIndication
Healthy VolunteerIndication
Muscular DystrophyIndication
Muscular DisordersIndication
AtrophicIndication
Muscular DiseasesIndication
Musculoskeletal DisordersIndication
Neuromuscular DisordersIndication
Nervous System DiseasesIndication
Genetic DiseasesIndication
InbornClinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular DystrophyStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
An Open-Label Extension Study to Assess the Long-term Effect of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents With Becker Muscular DystrophyStatus: , Estimated PCD: 2028-03-01
Clinical trial
A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part BStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular DystrophyStatus: Completed, Estimated PCD: 2024-03-01
Clinical trial
A Phase 1, Open-label Study in Healthy Male Subjects of the Absorption, Metabolism, Excretion, and Pharmacokinetics of EDG-5506 and an Absolute Bioavailability Study Using Radiolabeled EDG-5506Status: Completed, Estimated PCD: 2023-04-06